Predict your next investment

Asset/Investment Management
sectoral.com

See what CB Insights has to offer

Investments

40

Portfolio Exits

17

Funds

6

About Sectoral Asset Management

Sectoral Asset Management is an SEC-registered investment advisor based in Montreal whose focus is managing global equity portfolios by industry. Sectoral has also launched an alternative investment fund that offers an attractive exposure to the growing healthcare/biotech sector through both long and short positions.

Sectoral Asset Management Headquarter Location

1000 Sherbrooke Street Suite 2120

H3A 3G4,

Canada

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Sectoral Asset Management

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Sectoral Asset Management in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

382 items

Latest Sectoral Asset Management News

Mineralys Therapeutics Closes $118M Series B Financing

Jun 8, 2022

Mineralys Therapeutics, Inc. , a Philadelphia, PA-based clinical-stage biopharmaceutical company committed to developing a novel therapy for the treatment of hypertension, closed a $118m Series B financing. The round was led by RA Capital Management and Andera Partners with participation from new investors included RTW Investments, Rock Springs Capital, SR One Capital Management, Sectoral Asset Management, Ysios Capital, HealthCor Management and Boulder Ventures. Existing investors, including founding investment firm Catalys Pacific, Samsara BioCapital, HBM Healthcare Investments and Adams Street Partners also participated. As part of the Series B financing, Olivier Litzka, PhD, Partner, Andera Partners and Derek DiRocco, Partner, RA Capital Management will join the Mineralys Board of Directors. The company plans to use the proceeds to continue to advance MLS-101, a highly selective aldosterone synthase inhibitor. MLS-101 is currently being evaluated in a Phase 2 clinical trial, called Target-HTN, for patients with uncontrolled hypertension. Founded by Catalys Pacific and led by Jon Congleton, Chief Executive Officer, and BT Slingsby MD, PhD, MPH, Founder & Executive Chairman, Mineralys Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel therapy for the treatment of hypertension. The company is driven to bring a targeted approach to the management of hypertension via the development of MLS-101. MLS-101, licensed from Mitsubishi Tanabe Pharma Corporation, is a selective and potent aldosterone synthase inhibitor that is being investigated for the treatment of hypertension. FinSMEs 08/06/2022

Sectoral Asset Management Investments

40 Investments

Sectoral Asset Management has made 40 investments. Their latest investment was in Mineralys Therapeutics as part of their Series B on June 6, 2022.

CBI Logo

Sectoral Asset Management Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/8/2022

Series B

Mineralys Therapeutics

$118M

Yes

6

5/4/2022

Series C

Apnimed

$62.5M

Yes

3

1/25/2022

Series D

Magnolia Medical Technologies

$46M

Yes

2

11/3/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

9/23/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/8/2022

5/4/2022

1/25/2022

11/3/2021

9/23/2021

Round

Series B

Series C

Series D

Series B

Series A

Company

Mineralys Therapeutics

Apnimed

Magnolia Medical Technologies

Subscribe to see more

Subscribe to see more

Amount

$118M

$62.5M

$46M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

6

3

2

10

10

Sectoral Asset Management Portfolio Exits

17 Portfolio Exits

Sectoral Asset Management has 17 portfolio exits. Their latest portfolio exit was eFFECTOR Therapeutics on May 27, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/27/2021

Acq - Pending

$99M

2

2/24/2021

Acquired

$99M

4

10/30/2020

IPO

$99M

Public

1

8/7/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

10/3/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/27/2021

2/24/2021

10/30/2020

8/7/2020

10/3/2019

Exit

Acq - Pending

Acquired

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

2

4

1

10

10

Sectoral Asset Management Fund History

6 Fund Histories

Sectoral Asset Management has 6 funds, including New Emerging Medical Opportunities Fund IV.

Closing Date

Fund

Fund Type

Status

Amount

Sources

5/26/2020

New Emerging Medical Opportunities Fund IV

$96M

1

7/31/2015

New Emerging Medical Opportunities Fund III

Subscribe to see more

Subscribe to see more

10

10/31/2013

New Emerging Medical Opportunities Fund II

Subscribe to see more

Subscribe to see more

10

12/31/2007

New Emerging Medical Opportunities Fund I

Subscribe to see more

Subscribe to see more

10

New Emerging Medical Opportunities Funds II

$99M

10

Closing Date

5/26/2020

7/31/2015

10/31/2013

12/31/2007

Fund

New Emerging Medical Opportunities Fund IV

New Emerging Medical Opportunities Fund III

New Emerging Medical Opportunities Fund II

New Emerging Medical Opportunities Fund I

New Emerging Medical Opportunities Funds II

Fund Type

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$96M

$99M

Sources

1

10

10

10

10

Sectoral Asset Management Team

6 Team Members

Sectoral Asset Management has 6 team members, including current Chief Executive Officer, Jerome G Pfund.

Name

Work History

Title

Status

Michael Sjöström

Founder

Current

Jerome G Pfund

Chief Executive Officer

Current

Jean Bãƒâ©rard

Chief Financial Officer

Current

Marc-André Marcotte

Chief Operating Officer

Current

Elizabeth Lazaro

Managing Director

Current

Name

Michael Sjöström

Jerome G Pfund

Jean Bãƒâ©rard

Marc-André Marcotte

Elizabeth Lazaro

Work History

Title

Founder

Chief Executive Officer

Chief Financial Officer

Chief Operating Officer

Managing Director

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.